Open AccessA real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer
Author(s) -
Tsaur Igor,
Heidegger Isabel,
Bektic Jasmin,
Kafka Mona,
Bergh Roderick C. N.,
Hunting Jarmo C. B.,
Thomas Anita,
Brandt Maximilian P.,
Höfner Thomas,
Debedde Eliott,
Thibault Constance,
Ermacora Paola,
Zattoni Fabio,
Foti Silvia,
Kretschmer Alexander,
Ploussard Guillaume,
Rodler Severin,
Amsberg Gunhild,
Tilki Derya,
Surcel Christian,
Rosenzweig Barak,
Gadot Moran,
Gandaglia Giorgio,
Dotzauer Robert
Publication year - 2021
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.4184
Subject(s) - abiraterone acetate , prostate cancer , oncology , docetaxel , proportional hazards model , medicine , androgen deprivation therapy , log rank test , cancer
Background Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone‐sensitive prostate cancer (mHSPC). Real‐world data comparing different protocols are lacking yet. Thus, our objective was to compare the efficacy and safety of abiraterone acetate (AA)+ADT versus D+ADT in mHSPC. Methods In a retrospective multicenter analysis including males with mHSPC treated with either of the aforementioned protocols, overall survival (OS), progression‐free survival 1 (PFS1), and progression‐free survival 2 (PFS2) were assessed for both cohorts. Median time to event was tested by Kaplan–Meier method and log‐rank test. The Cox‐proportional hazards model was used for univariate and multivariate regression analyses. Results Overall, 196 patients were included. The AA+ADT cohort had a longer PFS1 in the log‐rank testing (23 vs. 13 mos., p < 0.001), a longer PFS2 (48 vs. 33 mos., p = 0.006), and longer OS (80 vs. 61 mos., p = 0.040). In the multivariate analyses AA+ADT outperformed D+ADT in terms of PFS1 (HR = 0.34, 95% CI = 0.183–0.623; p = 0.001) and PFS2 (HR = 0.33 95% CI = 0.128–0.827; p = 0.018), respectively, while OS and toxicity rate were similar between both groups. Conclusions AA+ADT is mainly associated with a similar efficacy and overall toxicity rate as D+ADT. Further prospective research is required for validation of the clinical value of the observed benefit of AA+ADT for progression‐free end‐points.